Surajit - Buccal Drug Delivery System

Views:
 
Category: Education
     
 

Presentation Description

No description available.

Comments

By: sirisha222 (7 month(s) ago)

hi its very impressive & informative so plz send dis to my mail

By: kranthireddy7 (8 month(s) ago)

pls i need ur ppt for my academics so i request u to send me this ppt on m.kranthi7@gmail.com.

By: prathap.sagi (11 month(s) ago)

sir plz send me u r ppt on prathap.sagi@gmail.com

By: rana1989 (11 month(s) ago)

sir, i m very impress abt ur presentation. SIR i want to do project on novel drug delivery systems topic .......so if possible plz send me this and also any other matter related with it on my id account drrangra@rediffmail.com thanking u .

By: quizking (12 month(s) ago)

Its a extreamly gud powerpoint. so plz send a copy of the same to me on syc0745@naver.com

See all

Presentation Transcript

Slide 1: 

WELCOME YOU ALL

Slide 2: 

BUCCAL DRUG DELIVERY SYSTEM BDDS SURAJIT SAHA M. Pharm 2nd Semester Dept. of Pharmaceutics

INTRODUCTION : 

INTRODUCTION The Buccal mucosa lines the inner cheek Placed between the upper gingivae and cheek Treat local and systemic conditions Typically large, hydrophilic and unstable proteins, oligonucleotides and polysaccharides

Slide 4: 

An ideal dosage regimen in the drug therapy of any disease is the one, which immediately attains the desired therapeutic concentration of drug in plasma (or at the site of action) and maintains it constant for the entire duration of treatment

ADVANTAGES : 

ADVANTAGES Avoids first pass effect Abundance of blood vessel Less hostile environment than GIT Ease of administration and termination Fast cellular recovery Directly & easily modify microenvironment Lower intersubject variability as compared to transdermal patches

Contd… : 

Contd… Permeability enhancers Rapid absorption possible & hence relatively rapid onset of action In comparison to TDDS, mucosal surfaces do not have a stratum corneum thus, the major barrier layer is absent

DISADVANTAGES : 

DISADVANTAGES Relatively small absorptive surface area (0.01 sq m vs 100 sq m for GIT) Movement affects mucoadhesive systems Less permeable than the small intestine Salivation and swallowing Taste of the drug

BUCCAL MUCOSA: ENVIRONMENT : 

BUCCAL MUCOSA: ENVIRONMENT The cells of the oral epithelia are surrounded by an intercellular ground substance, mucus The oral cavity is marked by the presence of saliva produced by the salivary glands Mucus which is secreted by the major and minor salivary glands as part of saliva

DRUG DELIVERY PATHWAYS : 

DRUG DELIVERY PATHWAYS Two possible routes of drug absorption through oral mucosa

BUCCAL DRUG DELIVERY AND MUCOADHESIVITY : 

BUCCAL DRUG DELIVERY AND MUCOADHESIVITY Mucoadhesion of the device is a key element The term ‘mucoadhesive’ is commonly used for materials that bind to the mucin layer of a biological membrane Achieve systemic delivery of drugs include tablets, patches, tapes, films, semisolids and powders

BIOADHESIVE DDSFOR MUCOSAL DRUG DELIVERY : 

BIOADHESIVE DDSFOR MUCOSAL DRUG DELIVERY

MUCOADHESIVE POLYMERS : 

MUCOADHESIVE POLYMERS GENERAL PHYSIOCHEMICAL FEATURES Predominantly anionic hydrophilicity with numerous hydrogen bond-forming groups Suitable surface property for wetting mucus/mucosal tissue surfaces and Sufficient flexibility to penetrate the mucus network or tissue crevices

POLYMER : 

POLYMER

CONSIDERATION : 

CONSIDERATION The drug must resist, or be protected by salivary and tissue enzymes The drug and adhesive materials must not damage the teeth, oral cavity No keratinolysis, discoloration, and irritation

FACTORS AFFECTING DRUG DELIVERY VIA BUCCAL ROUTE : 

FACTORS AFFECTING DRUG DELIVERY VIA BUCCAL ROUTE Hydrophilic macromolecules such as peptides, absorption enhancers have been used Smaller molecules greater transport No ionized forms have greater transport More lipid soluble higher its permeability More partition coefficient more permeability Lipid-soluble drug stores in Obese individuals

DESIGN OF BUCCAL DOSAGE FORM : 

DESIGN OF BUCCAL DOSAGE FORM Matrix type: The Buccal patch designed in a matrix configuration contains drug, adhesive, and additives mixed together Bi-directional patches release drug in both the mucosa and the mouth Drug + Mucoadhesive Matrix …………………………………………………………………. ………………………………………………………………….

Contd… : 

Contd… Reserviour type: The buccal patch designed in a reservoir system contains a cavity for the drug and additives separate from the adhesive Impermeable backing is applied to control the direction of drug delivery; to reduce patch deformation and disintegration while in the mouth; and to prevent drug loss Backing Layer Drug + Mucoadhesive Matrix ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

BUCCAL MUCOADHESIVE DOSAGE FORMS : 

BUCCAL MUCOADHESIVE DOSAGE FORMS Three types based on their geometry

BUCCAL FORMULATION : 

BUCCAL FORMULATION

Contd… : 

Contd…

EXPERIMENTAL METHODOLOGY FOR BUCCAL PERMEATION STUDIES : 

EXPERIMENTAL METHODOLOGY FOR BUCCAL PERMEATION STUDIES EVALUATION In vitro Methods In vivo Methods

IN VITRO EVALUATION : 

IN VITRO EVALUATION Percentage increase in weight Swelling properties of films Shear stress method Folding endurance Diffusion study Thickness study

IN VIVO EVALUATION : 

IN VIVO EVALUATION 1 2 3 4 5 Intelli Drug Device

ACTIVE INGREDIENTS DELIVERED VIA A BUCCAL ROUTE : 

ACTIVE INGREDIENTS DELIVERED VIA A BUCCAL ROUTE

RECENT & FUTURE OF BDDS : 

RECENT & FUTURE OF BDDS Buccal nitroglycerin, can use for acute therapy for an anginal attack as well as for chronic prophylaxis Novel liquid aerosol formulation of insulin Development of suitable delivery devices, permeation enhancement, and Buccal delivery of drugs that undergo a first-pass effect, such as cardiovascular drugs, analgesics, and peptides Research yield some successes Promote further research; more companies Rest depend on delivery technology

CONCLUTION : 

CONCLUTION Buccal drug delivery is a promising area for systemic delivery of orally inefficient drugs as well as an attractive alternative for noninvasive delivery of potent peptide and perhaps protein drug molecules

REFERENCES : 

REFERENCES Michael J Rathbone, in: Oral Mucosal Drug Delivery M.S. Wani*, Dr. S.R. Parakh, Dr. M.H. Dehghan, S.A. Polshettiwar, V.V. Chopade, V.V. Pande, in: Current Status In Buccal Drug Delivery System: A review Amir H Shojaei, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada  T6G 2N8, in: Buccal Mucosa As A Route For Systemic Drug Delivery: A Review Yie W. Chien, in: Novel Drug Delivery System Hitesh R. Patel*, Dr. M.M. Patel, in: Draw Attention Towards Mucoadhesive Buccal Drug Delivery System Bio-Images Research Ltd, in: Applications of gamma scintigraphy in oral drug delivery

Slide 31: 

THANK YOU